Top

Taking a novel approach to drug development

Clinical Trials

Lantern Pharma is recruiting for multiple clinical trials:
1) LP-300 for never smokers with NSCLC Adenocarcinoma
2) LP-184 for multiple solid tumors and GBM
3) LP-284 for non-Hodgkin's lymphoma

See more information below.

The Harmonic™ Clinical Trial is enrolling participants in a Phase 2 multi-center study to evaluate an investigational new drug called LP-300.

This trial is for never smokers with relapsed advanced primary adenocarcinoma of the lung, which is a type of non-small cell lung cancer (NSCLC).

LP-300 for Never-smokers with NSCLC Adenocarcinoma 

STAGE

Phase 2

DISEASE

Non-Small Cell Lung Cancer

TREATMENT

LP-300 + Carboplatin and Pemetrexed

LOCATION OF TRIAL

Multiple Sites

ClinicalTrials.gov ID

NCT05456256

The FDA has authorized the launch of our Phase 2 clinical trial (the “Harmonic™ Trial”) of LP-300 in combination with carboplatin and pemetrexed in never smoker patients with relapsed advanced primary adenocarcinoma of the lung after treatment with tyrosine kinase inhibitors. Our purpose in conducting the study is to determine the potential clinical advantages for this drug combination in the study-defined patient population. 

The trial is designed as a multicenter, open label, Phase 2 trial with planned enrollment of approximately 90 patients. Patients who are never smokers with lung adenocarcinoma and have relapsed after prior treatment with tyrosine kinase inhibitors will be eligible for enrollment. Following a six-patient safety lead-in stage, the trial will consist of randomization in a 2:1 allocation ratio to one of two arms: Arm A (consisting of carboplatin, pemetrexed, and LP-300) or Arm B (consisting of carboplatin and pemetrexed).

For more information on the Harmonic™ clinical trial, please visit www.harmonictrial.com or the ClinicalTrials.gov study page.

LP-184 in Patients With Advanced Solid Tumors

STAGE

Phase 1A

DISEASE

Advanced or Metastatic Solid Tumors, or Unresectable or Recurrent GBM

TREATMENT

LP-184

LOCATION OF TRIAL

Multiple Sites

ClinicalTrials.gov ID

NCT05933265

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184.

For more information on the ongoing Phase 1A study of LP-184 in patients with advanced solid tumors, please visit the
study page.

LP-284 for the Treatment of Relapsed or Refractory Non-Hodgkin’s lymphoma (NHL)

STAGE

Phase 1

DISEASE

Relapsed or refractory non-Hodgkin’s lymphoma and solid tumors

TREATMENT

LP-284

LOCATION OF TRIAL

Multiple sites

ClinicalTrials.gov ID

NCT06132503

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.

For more information on the ongoing Phase 1 study of LP-284 in patients with relapsed or refractory lymphomas and solid tumors, please visit the study page.

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.